How to Buy Sutro Biopharma Stock
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
Sutro Biopharma stock last closed at $0.88, down 2.45% from the previous day, and has decreased 75.14% in one year. It has overperformed other stocks in the Biotechnology industry by 0.02 percentage points. Sutro Biopharma stock is currently +67.3% from its 52-week low of $0.52, and -83.08% from its 52-week high of $5.17.
There are currently 83.78M STRO shares outstanding. The market capitalization of STRO is $73.30M. In the last 24 hours, 3.57M STRO shares were traded.
How to Buy Sutro Biopharma Stock
Not sure how to invest in Sutro Biopharma stock? Here's how.
- Figure out where to buy Sutro Biopharma stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Sutro Biopharma stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Choose your method of payment and add your info.
- Analyze Sutro Biopharma stock: The Sutro Biopharma ticker symbol is STRO. Is Sutro Biopharma stock a good investment? Should you buy shares of STRO? How do STRO's underlying business fundamentals look? Do top analysts think Sutro Biopharma is a good buy? Why has STRO's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if STRO is a good stock to buy).
- Execute your STRO buy order: Decide if you will purchase STRO shares at the current market price or use a limit order to buy STRO stock at a specific price.
- Keep tabs on your STRO position: Create a watchlist to keep tabs on your position in Sutro Biopharma shares.
Step 1: Figure out where to buy Sutro Biopharma stock
You will need an online brokerage account in order to access the NASDAQ market and buy STRO shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Tech to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal info so you are able to buy STRO stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start your new trading account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have created your account on the best investment app, you can securely and quickly fund your account:
Check out the video below if you need help transferring funds into your new investment account.
Step 4: Analyze Sutro Biopharma stock
After you have selected the best place to buy Sutro Biopharma stock, it's very important to research their stock prior to investing, so you can understand the risk and upside.
Sutro Biopharma Metrics
STRO Due Diligence Score
WallStreetZen was built to help average investors do better fundamental analysis in less time.
You can view all of the due diligence checks on STRO's stock page.
Is STRO stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge STRO's fair value.
Using relative valuations ratios:
- STRO could be undervalued based on its P/B ratio of 1.64x, relative to Biotechnology industry P/B ratio of 4.37x
You can do additional valuation research on STRO's stock here.
STRO Financials at a glance
Passed Health Checks:
- There are more short-term assets than long-term liabilities on the STRO balance sheet.
- STRO has cash burn of 194638000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the STRO balance sheet.
Failed Health Checks:
- STRO has a relatively high debt to equity ratio of 7.68.
- STRO has $317.75M in cash and short term investments. This is not sufficient to cover its annual cash burn of $194.64M.
- STRO profit margin has gone down from -69.5% to -366.6% in the past year.
- Total STRO debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy STRO stock, according to analysts?
Out of 5 Equities analysts who give ratings on STRO, the consensus analyst rating on Sutro Biopharma is a Hold
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Latest STRO Analyst Ratings
Reni Benjamin, a bottom 5% analyst from JMP Securities reiterates STRO with a buy rating and maintains their STRO price target from $17.00 to $17.00, on Dec 11, 2024.
You can dig deeper into what analysts are projecting on the Sutro Biopharma stock forecast page.
STRO Technical Indicators
How is STRO performing as a company?
Last year, STRO revenue was $62.04M. During the past five year, STRO's revenue has grown by 7.74% per year. This was slower than the Biotechnology industry average of 45.47%.
You can research STRO's earnings and revenue performance here.
What are STRO insiders up to?
Over the past 12 months, executives and large shareholders at STRO have sold more shares than they have bought.
Venkatesh Srinivasan, CHIEF TECH OP OFFICER of STRO, was the latest STRO insider to sell. They sold $4,561.80 worth of STRO stock on Apr 11, 2025.
Get more info about who owns STRO stock here.
Does STRO provide a stable income stream?
No, Sutro Biopharma doesn't provide an income stream by paying out dividends.
What others are saying about STRO
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Execute your STRO buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a given price, place a limit order.
Hit the Open button and eToro will place the order.
If you require more help with buying stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your STRO position
Now that you own some shares in STRO, you'll want to stay up-to-date on your new company.
Put STRO on a watchlist to get notified of important updates regarding your STRO stock.
STRO Feed
How to Buy Stock in Sutro Biopharma
To summarize, here are the 6 steps for buying Sutro Biopharma stock:
- Figure out where to buy Sutro Biopharma stock
- Create your brokerage account
- Put funds into your investment account
- Analyze Sutro Biopharma stock
- Execute your STRO buy order
- Keep tabs on your STRO position
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Sutro Biopharma, click below.
Other Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.